热门资讯> 正文
Elicio Therapeutics发布了自然医学1期AMPLUTE-201研究的后续数据
2025-08-12 20:11
- At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months
- Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS ("mKRAS") induced by ELI-002
- 77% reduction in the risk of death and 88% reduction in the risk of relapse, associated with T cell responses above the threshold for anti-tumor efficacy
- ELI-002 induced both CD4+ and CD8+ mKRAS-specific T cell responses in most patients, and evidence of antigen-spreading to patient-specific neoantigens not included in ELI-002 was observed
- Final event-driven disease-free survival ("DFS") analysis for the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P monotherapy in pancreatic ductal adenocarcinoma ("PDAC") is anticipated in Q4 2025
- Final event-driven disease-free survival ("DFS") analysis for the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P monotherapy in pancreatic ductal adenocarcinoma ("PDAC") is anticipated in Q4 2025
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
